Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma

Hadj,Jamal  Oulad; den Braven,Rogier; Tillier,Corrine; Schrijver,Hans  M.; Verheul,Henk  M.W.; van der Vliet,Hans  J.

doi:10.3892/ol.2012.646

Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma

Authors:
- Jamal Oulad Hadj
- Rogier den Braven
- Corrine Tillier
- Hans M. Schrijver
- Henk M.W. Verheul
- Hans J. van der Vliet
View Affiliations

Affiliations: VU University Medical Center, Department of Medical Oncology, 1081 HV Amsterdam, The Netherlands, Westfriesgasthuis, Department of Neurology, 1624 NP Hoorn, The Netherlands
Published online on: March 16, 2012 https://doi.org/10.3892/ol.2012.646
Pages: 1293-1296

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sunitinib is an oral receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity that is approved for the treatment of advanced renal cell carcinoma (RCC), malignant gastrointestinal stromal tumors and pancreatic neuroendocrine tumors. Well-known side effects of sunitinib include hypertension, fatigue, thyroid dysfunction, cardiotoxicity, gastrointestinal toxicity and skin toxicity. In this study, we report the case of a 61-year-old male with papillary metastatic RCC who responded to sunitinib but developed generalized tonic-clonic seizures during the third cycle. Magnetic resonance imaging (MRI) was compatible with reversible posterior leukoencephalopathy syndrome (RPLS). After the administration of anti-epileptic drugs and the withdrawal of sunitinib there was rapid clinical improvement. Notably, radiological characteristics of RPLS persisted during second-line therapy with the mammalian target of rapamycin (mTOR) inhibitor everolimus and only resolved when everolimus was terminated due to disease progression. Although sunitinib-induced RPLS has been reported previously, our case is the first to additionally suggest that everolimus may sustain and therefore potentially contribute to the occurrence of RPLS.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J, et al: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2000. View Article : Google Scholar : PubMed/NCBI
2	van der Veldt AA, Haanen JB, van den Eertwegh AJ, et al: Targeted therapy for renal cell cancer: current perspectives. Discov Med. 10:394–405. 2010.PubMed/NCBI
3	Linehan WM, Zbar B, Bates SE, et al: Cancer of the kidney and ureter. Cancer: Principles and Practice of Oncology. 6th edition. DeVita VT Jr, Hellman S and Rosenberg SA: Lippincott Williams & Wilkins; Philadelphia: pp. 1362–1396. 2001
4	Powles T, Chowdury S, Jones R, et al: Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer. 104:741–745. 2011. View Article : Google Scholar : PubMed/NCBI
5	Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
6	Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 372:449–456. 2008. View Article : Google Scholar : PubMed/NCBI
7	Motzer RJ, Escudier B, Oudard S, et al: Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer. 116:4256–4265. 2010. View Article : Google Scholar : PubMed/NCBI
8	Verheul HM and Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 7:475–485. 2007. View Article : Google Scholar : PubMed/NCBI
9	Padhy BM, Shanmugam SP, Gupta YK, et al: Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy. Br J Clin Pharmacol. 71:777–779. 2011. View Article : Google Scholar : PubMed/NCBI
10	Choueiri TK, Plantade A, Elson P, et al: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 26:127–131. 2008. View Article : Google Scholar : PubMed/NCBI
11	Hinchey J, Chaves C, Appignani B, et al: A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 334:494–500. 1996. View Article : Google Scholar
12	Martín G, Bellido L and Cruz JJ: Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 25:35592007.
13	Medioni J, Cojocarasu O, Banu E, et al: Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targ Oncol. 2:193–195. 2007. View Article : Google Scholar
14	Cumurciuc R, Martinez-Almoyna L, Henry C, et al: Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris). 164:605–607. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chen A and Agarwal N: Reversible posterior leucoencephalo-pathy syndrome associated with sunitinib. Intern Med J. 39:341–342. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kapiteijn E, Brand A, Kroep J, et al: Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 18:1745–1747. 2007. View Article : Google Scholar
17	Fugate JE, Claassen DO, Cloft HJ, et al: Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 85:427–432. 2010. View Article : Google Scholar : PubMed/NCBI
18	Govindarajan R, Adusumilli J, Baxter DL, et al: Reversible posterior leukencephalopathy syndrome induced by RAF kinase inhibitor BAY 43–9006. J Clin Oncol. 24:e482006.PubMed/NCBI
19	Glusker P, Recht L and Lane B: Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 354:980–981. 2006. View Article : Google Scholar : PubMed/NCBI
20	Ozcan C, Wong SJ and Hari P: Reversible posterior leukencephalopathy syndrome and bevacizumab. N Engl J Med. 354:981–982. 2006.
21	Paulson OB, Strandgaard S and Edvinsson L: Cerebral autoregulation. Cerebrovasc Brain Metab Rev. 2:161–192. 1990.
22	Covarrubias DJ, Luetmer PH and Campeau NG: Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 23:1038–1048. 2002.
23	Ito Y, Arahata Y, Goto Y, et al: Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome. AJNR Am J Neuroradiol. 19:415–417. 1998.PubMed/NCBI
24	Agarwala SS and Case S: Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist. 15:236–245. 2010. View Article : Google Scholar : PubMed/NCBI
25	Schwartz RB: A reversible posterior leukencephalopathy syndrome. N Engl J Med. 334:17431996. View Article : Google Scholar : PubMed/NCBI
26	Weingarten K, Barbut D, Fillipi C, et al: Acute hypertensive encephalopathy: findings on spin-echo and gradient-echo MR-imaging. Am J Roentgenol. 162:665–670. 1994. View Article : Google Scholar : PubMed/NCBI